| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $8,053,130 | 26 | 100 |
| Riley Jennifer | Chief Strategy Officer | 0 | $0 | 1 | $52,012 | $-52,012 |
| Chan Mitchell | director | 0 | $0 | 1 | $72,461 | $-72,461 |
| Goldman Jonathan | director | 0 | $0 | 1 | $162,937 | $-162,937 |
| VARKI PAUL | Chief Legal Officer | 0 | $0 | 1 | $1.51M | $-1.51M |
| Doyle Mittie | Chief Medical Officer | 0 | $0 | 13 | $2.98M | $-2.98M |
| Sullivan Christopher Ryan | Chief Financial Officer | 0 | $0 | 9 | $3.27M | $-3.27M |
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to …
Over the last 12 months, insiders at Avalo Therapeutics, Inc. have bought $0 and sold $8.05M worth of Avalo Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Avalo Therapeutics, Inc. have bought $1.78M and sold $5.11M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500 shares for transaction amount of $6,500 was made by Almenoff June Sherie (director) on 2024‑11‑13.
| 2026-09-16 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 12,394 0.0232% | $16.33 | $202,437 | -19.57% | |
| 2026-09-10 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 10,185 0.0199% | $17.62 | $179,457 | -20.93% | |
| 2026-08-28 | Sale | Doyle Mittie | Chief Medical Officer | 679 0.0016% | $20.00 | $13,580 | -23.58% | |
| 2026-08-18 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 31,031 0.0601% | $20.05 | $622,324 | -21.87% | |
| 2026-08-17 | Sale | Doyle Mittie | Chief Medical Officer | 1,000 0.0023% | $20.00 | $20,000 | -22.46% | |
| 2026-08-17 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 41,694 0.0952% | $19.86 | $828,096 | -22.46% | |
| 2026-08-11 | Sale | Riley Jennifer | Chief Strategy Officer | 2,655 0.0051% | $19.59 | $52,012 | -19.26% | |
| 2026-08-10 | Sale | Doyle Mittie | Chief Medical Officer | 679 0.0016% | $20.00 | $13,580 | -19.60% | |
| 2026-07-27 | Sale | Doyle Mittie | Chief Medical Officer | 1,000 0.0091% | $20.00 | $20,000 | -15.18% | |
| 2026-06-30 | Sale | Doyle Mittie | Chief Medical Officer | 4,654 0.0446% | $20.00 | $93,080 | -1.62% | |
| 2026-06-23 | Sale | Doyle Mittie | Chief Medical Officer | 1,450 0.013% | $18.00 | $26,100 | +2.08% | |
| 2026-05-28 | Sale | Doyle Mittie | Chief Medical Officer | 679 0.006% | $16.00 | $10,864 | +6.85% | |
| 2026-05-15 | Sale | Doyle Mittie | Chief Medical Officer | 3,000 0.0281% | $18.76 | $56,280 | -6.48% | |
| 2026-05-06 | Sale | VARKI PAUL | Chief Legal Officer | 75,063 0.6145% | $20.17 | $1.51M | -21.23% | |
| 2026-05-06 | Sale | Doyle Mittie | Chief Medical Officer | 106,555 0.8946% | $20.68 | $2.2M | -21.23% | |
| 2026-05-06 | Sale | Chan Mitchell | director | 3,167 0.0294% | $22.88 | $72,461 | -21.23% | |
| 2026-05-06 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 47,000 0.3852% | $20.19 | $948,722 | -21.23% | |
| 2026-05-05 | Sale | Doyle Mittie | Chief Medical Officer | 1,679 0.0146% | $16.00 | $26,864 | +6.00% | |
| 2026-04-30 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 8,457 0.075% | $13.23 | $111,853 | +27.46% | |
| 2026-04-29 | Sale | Sullivan Christopher Ryan | Chief Financial Officer | 8,458 0.0743% | $13.09 | $110,736 | +27.92% |
| Sullivan Christopher Ryan | Chief Financial Officer | 39900 0.0744% | $289,275.00 | 4 | 9 | |
| Boyd Steven | 47576000 88.7116% | $344.93M | 2 | 0 | ||
| Ball Gary Edward | President | 15500000 28.9017% | $112.38M | 1 | 0 | |
| Moscato Robert Jr. | COO | 2592743 4.8345% | $18.8M | 1 | 0 | |
| ARMISTICE CAPITAL, LLC | 10 percent owner | 731458 1.3639% | $5.3M | 164 | 2 | |
| Greenleaf Peter | Chief Executive Officer | 412500 0.7692% | $2.99M | 1 | 0 | |
| Pedder Simon | Executive Chairman of the Bd | 262734 0.4899% | $1.9M | 2 | 0 | |
| COLA MICHAEL F | Chief Executive Officer | 175746 0.3277% | $1.27M | 1 | 0 | |
| Calias Pericles | Chief Scientific Officer | 52462 0.0978% | $380,349.50 | 2 | 0 | |
| Miller Joseph M | Chief Financial Officer | 48777 0.091% | $353,633.25 | 2 | 0 | |
| Harrell James Archie Jr | Chief Commercial Officer | 36766 0.0686% | $266,553.50 | 8 | 0 | |
| Marcus Ronald | Chief Medical Officer | 36000 0.0671% | $261,000.00 | 1 | 0 | |
| Wilkins H Jeffrey | Chief Medical Officer | 33373 0.0622% | $241,954.25 | 2 | 0 | |
| Hacksell Uli | director | 20000 0.0373% | $145,000.00 | 2 | 0 | |
| NEIL GARRY ARTHUR | CEO and Chairman of the Board | 13220 0.0247% | $95,845.00 | 6 | 0 | |
| Greenway Schond L. | CFO | 3883 0.0072% | $28,151.75 | 2 | 0 | |
| Almenoff June Sherie | director | 1000 0.0019% | $7,250.00 | 2 | 0 | <0.0001% |
| Phillips Matthew V | Chief Commercial Officer | 1020 0.0019% | $7,395.00 | 2 | 0 | |
| Caissa Capital Management ltd. | 10 percent owner | 0 0% | $0 | 32 | 0 |
$3,887,391 | 114 | 13.01% | $433.37M | |
$31,123,523 | 108 | 6.46% | $387.86M | |
$24,384,691 | 42 | -30.27% | $396.82M | |
$2,481,409 | 33 | 201.68% | $455.48M | |
$22,020,194 | 25 | 38.25% | $405.58M |
| Increased Positions | 61 | +89.71% | 7M | +44.56% |
| Decreased Positions | 29 | -42.65% | 2M | -15.58% |
| New Positions | 33 | New | 3M | New |
| Sold Out Positions | 15 | Sold Out | 804,777 | Sold Out |
| Total Postitions | 100 | +47.06% | 20M | +28.98% |
| Bvf Inc/Il | $23,066.00 | 7.53% | 1.36M | +327,207 | +31.83% | 2025-09-30 |
| Orbimed Advisors Llc | $22,965.00 | 7.5% | 1.35M | +382,300 | +39.53% | 2025-09-30 |
| Nantahala Capital Management, Llc | $21,020.00 | 6.86% | 1.24M | +240,000 | +24.12% | 2025-09-30 |
| Point72 Asset Management, L.P. | $17,939.00 | 5.86% | 1.05M | +1M | New | 2025-09-30 |
| Affinity Asset Advisors, Llc | $17,126.00 | 5.59% | 1.01M | +398,345 | +65.53% | 2025-09-30 |
| Caligan Partners Lp | $14,183.00 | 4.63% | 833,333 | +833,333 | New | 2025-09-30 |
| Balyasny Asset Management L.P. | $13,913.00 | 4.54% | 817,436 | +817,436 | New | 2025-09-30 |
| Silverarc Capital Management, Llc | $12,270.00 | 4.01% | 720,922 | +720,922 | New | 2025-09-30 |
| Vanguard Group Inc | $11,789.00 | 3.85% | 692,637 | +525,696 | +314.9% | 2025-09-30 |
| Ra Capital Management, L.P. | $11,284.00 | 3.68% | 662,968 | -270,005 | -28.94% | 2025-09-30 |